

**Remarks**

Responsive to the Restriction Requirement mailed March 11, 2003, Applicants elect Group XV (Claims 46-52) and the following species: Category 1) Group A: IKK-I, and Group B: SPA-1.

Applicants withdraw all pending claims and add claims substantially corresponding to Group XV. The new claims are directed towards a method of screening for drug candidates capable of modulating the interaction of the proteins of a protein complex. It is believed that this amendment eliminates the requirement to elect species from Categories 2-6 because the now claims do not contain a genus or species from Categories 2-6. This amendment is supported by the application as-filed and no new matter has been added.

Respectfully submitted,

  
Andrew Gibbs  
Agent for Applicants  
Registration No. 52,943


Intellectual Property Department  
**Myriad Genetics, Inc.**  
320 Wakara Way  
Salt Lake City, UT 84108  
Telephone: 801-584-3600  
Fax: 801-883-3871

**CERTIFICATE OF EXPRESS MAIL**

"Express Mail" mailing label number EV 295123569 US  
Date of Deposit: April 11, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231.

  
Michael Moreno

  
Date